Detalhe da pesquisa
1.
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
Retrovirology
; 10: 43, 2013 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-23602046
2.
HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.
J Virol
; 85(9): 4330-42, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21345957
3.
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
Retrovirology
; 8: 89, 2011 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-22054077
4.
Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
AIDS Res Hum Retroviruses
; 33(12): 1220-1235, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28797170
5.
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.
Antivir Chem Chemother
; 27: 2040206619895706, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31856576
6.
The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets.
Virology
; 442(1): 51-8, 2013 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-23602007